Clusterin, Ptx3 and Pediatric Febrile Neutropenia (CluPPFeN)
NCT ID: NCT05584930
Last Updated: 2024-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
55 participants
INTERVENTIONAL
2022-10-10
2024-08-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This acquired deficiency of immunity mainly causes susceptibility to bacterial and fungal infections, pathogens normally recognized by specific receptors of innate immunity (Pattern Recognition Receptor, PRR).
Thus, the febrile episodes in the context of post-chemotherapy neutropenia can be bacterial or fungal etiology, but can also frequently be related to viral infections, toxic phenomena or other etiologies. In the absence of a discriminating marker, treatment for all these children is based on early, broad-spectrum antibiotic therapy in hospital. Septic shock or even death by refractory septic shock remain, even if they are rare, real complications in pediatric oncology, requiring discriminatory markers for effective management, While trying to reduce the number and duration of hospitalizations for children at low risk for severe febrile aplasia.
It is therefore necessary to identify other markers allowing the earliest possible classification of episodes of febrile aplasia.
A previous study, conducted by our team, PTX3 and febrile aplasia, studied pentraxin 3 (PTX3), a soluble PRR of the pentraxin family that plays a key role in immune surveillance against pathogens. Preliminary results obtained from samples from a cohort of patients treated in adult hematology and pediatric onco-hematology support a prognostic character of PTX3 in the severity of aplasia, with higher elevations of serum protein during episodes of severe sepsis or septic shock (ongoing analyses and interpretations for the adult population). The available data to date on the pediatric cohort are insufficient to conclude on the value of using PTX3. The investigators therefore wish to create a new paediatric cohort, in order to evaluate the PTX3 levels for the paediatric population and also to perform the assay of a new marker, clusterin.
Clusterin (CLU) is an extracellular chaperone protein of constitutive expression. The Innate Immunity team of the National Institute of Health and Medical Research (INSERM) "1307-Scientific Research National Center (CNRS) 6075" unit has shown that Clu binds to extracellular histones and inhibits their inflammatory, thrombotic and cytotoxic properties. The investigators also observed (i) that in adults without severe sepsis neutropenics, low serum levels of Clu at intake and lack of normalization of rates are associated with higher mortality and (ii) Clu levels are inversely correlated with circulating histone levels. All these data suggest that Clu would have a protective role for histone-induced lesions during sepsis independently of antibiotic treatment, opening an innovative therapeutic pathway in the management of severe sepsis.
CluPPFeN is based on the hypothesis that, in a pediatric population with episodes of febrile aplasia, serum Clu and serum PTX3 levels would discriminate between febrile episodes caused by bacterial infection and other etiologies and, As a result, would reduce the consumption of antibiotics, which provide resistance, and the length of hospitalization.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Evaluate serum levels CLU levels during febrile neutropenia in children followed for cancer.
-Secondary objective :
1. Evaluate serum levels of CLU at the beginning of non-febrile aplasia and during a possible 2nd febrile peak
2. Evaluate serum PTX3 levels during febrile neutropenia in children followed for cancer
3. Explore the association between CLU, PTX3 and the severity of the aplasia episode
4. Evaluate the association between CLU and PTX3 levels and the type of pathogen found during febrile aplasia
5. Exploration of the diagnostic contribution of CLU and PTX3 in relation to other known parameters of inflammation (including C reactive protein (CRP), procalcitonin (PCT), fibrinogen, interleukin 1 (IL-1), IL-6, IL-10, Tumor Necrosis Factor (TNF-α), CXCL8, IL17)
6. Exploration of genetic polymorphisms predisposing to bacterial and fungal infections (including PTX3 and CLU gene polymorphisms) in the context of febrile aplasia
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cancer patient
Collection of blood sample
Collection of blood sample
* Visit 1 : At inclusion (day 1 of chemotherapy treatment)
* Visit 2 : Onset of aplasia
* Visit 3a : day 1 of the 1st febrile aplasia
* Visit 3b : day 3 of the 1st febrile episode
* Visit 3c : day 8 of the 1st febrile episode
* Visit 4a : second febrile episode (after 7 days)
* Visit 4b : day 3 of the second febrile episode (after 7 days)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Collection of blood sample
* Visit 1 : At inclusion (day 1 of chemotherapy treatment)
* Visit 2 : Onset of aplasia
* Visit 3a : day 1 of the 1st febrile aplasia
* Visit 3b : day 3 of the 1st febrile episode
* Visit 3c : day 8 of the 1st febrile episode
* Visit 4a : second febrile episode (after 7 days)
* Visit 4b : day 3 of the second febrile episode (after 7 days)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalized for chemotherapy leading to febrile aplasia
* Signature of the informed consent of the parents or holder of parental authority and consent of the patient
Exclusion Criteria
* Child with less than 5 kg body weight at inclusion
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Angers
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Coralie MALLEBRANCHE, Dr
Role: PRINCIPAL_INVESTIGATOR
UH Angers
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Angers
Angers, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A01750-43
Identifier Type: -
Identifier Source: org_study_id